V. Trillet-lenoir, MD

Articles by V. Trillet-lenoir, MD

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

ByJean-marc A. Nabholtz, MD,B. Thuerlimann, MD,W. R. Bezwoda, MD,D. Melnychuk, MD,L. Deschênes, MD,J. Douma, MD,T. A. Vandenberg, MD,B. Rapoport, MD,R. Rosso, MD,V. Trillet-lenoir, MD,J. Drbal, MD,Matti S. Aapro, MD,M. Alaki, MD,M. Murawsky, MD,Allesandro Riva, MD

August 1st 1997

This nonblinded, multicenter, randomized phase III study compares the median time to progression (primary endpoint), response rate, and quality of life, safety, and survival of

Latest Updated Articles

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer
Published: August 1st 1997 | Updated:

V. Trillet-lenoir, MD

Articles by V. Trillet-lenoir, MD

Docetaxel vs Mitomycin Plus Vinblastine in Anthracycline-Resistant Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment

FDA Grants Fast Track Designation to MT-125 in Glioblastoma

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma